STME (Stimcell Energetics) Current Deferred Revenue: $0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STME Stimcell Energetics Inc STME
26 GF Score
Price $0.28
! 4 Warning Signs
View Full Analysis

What is Stimcell Energetics Current Deferred Revenue?

Stimcell Energetics STME 26 Current Deferred Revenue is $0.00 Mil as of Feb. 2026. GuruFocus rates STME with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Stimcell Energetics's current deferred revenue for the quarter that ended in Feb. 2026 was $0.00 Mil.

Stimcell Energetics Current Deferred Revenue Related Terms

Stimcell Energetics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Stimcell Energetics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stimcell Energetics Current Deferred Revenue Chart

Stimcell Energetics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Stimcell Energetics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STME
26GF Score
Stimcell Energetics Inc STME
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Stimcell Energetics (STME) has a Current Deferred Revenue of $0.00 Mil as of Feb. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Stimcell Energetics and its competitors.
Is Stimcell Energetics' Current Deferred Revenue too high?
Stimcell Energetics' current Current Deferred Revenue is $0.00 Mil. Overall, Stimcell Energetics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' Current Deferred Revenue compare to NVNO and TRIB?
Stimcell Energetics' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Stimcell Energetics and its competitors. Stimcell Energetics's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Stimcell Energetics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Stimcell Energetics (STME), the current Current Deferred Revenue is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stimcell Energetics Business Description

Address 1130 Pender Street, West, Suite 820, Vancouver, BC, CAN, V6E 4A4
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
26GF Score

Get the complete analysis for STME

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price